ImmunityBio (NASDAQ:IBRX) Shares Down 8.6% - Should You Sell?

Key Points

• Shares fell 8.6% (to about $7.38) on Thursday with 27.4M shares traded as an FDA warning over allegedly misleading ANKTIVA promotional claims triggered a sharp negative market reaction and raised regulatory and litigation risk (multiple plaintiff firms have opened investigations).
• Offsetting news: an IDMC power check kept the pivotal BCG‑naïve NMIBC trial adequately powered and the company’s supplemental BLA timeline for 2026 intact, ANKTIVA gained approval in Macau, and analysts currently rate the stock a consensus "Moderate Buy" with an average price target of about $14.40.
• Corporate note: insiders have sold roughly 501,967 shares in the last 90 days but still collectively own 69.48% of the stock, a concentration that can affect liquidity and investor considerations.

Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) traded down 8.6% on Thursday . The stock traded as low as $7.22 and last traded at $7.38. 27,415,437 shares were traded during mid-day trading, a decline of 32% from the average session volume of 40,060,570 shares. The stock had previously closed at $8.07.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: IDMC finds the pivotal randomized BCG‑naïve NMIBC trial remains adequately powered to detect a clinically meaningful difference between ANKTIVA® + BCG and BCG alone — this supports ImmunityBio’s planned supplemental BLA timeline for 2026. ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG‑Naïve NMIBC Trial…
• Positive Sentiment: ImmunityBio announced regulatory approval for ANKTIVA® in Macau SAR, expanding the product’s commercial footprint in Asia. ImmunityBio Inc. (IBRX) Announces Approval for ANKTIVA® in Macau SAR, China
• Positive Sentiment: An analyst firm (D. Boral Capital) reiterated a Buy view on IBRX, a bullish signal for investors focused on fundamentals and the company’s commercial prospects. ImmunityBio NASDAQ: IBRX Earns "Buy" Rating from D. Boral Capital
• Neutral Sentiment: Coverage and analysis: Zacks investigated why IBRX is down since its last earnings report, useful context but not a single catalytic event. Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report?
• Neutral Sentiment: Market note: a premarket report highlighted the trial power check and noted the stock’s strong YTD rally, providing market context for recent volatility. ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check
• Negative Sentiment: FDA issued a warning/letter flagging misleading claims in Anktiva promotional materials and a podcast, which triggered a sharp negative market reaction and regulatory risk around marketing practices. IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims
• Negative Sentiment: Multiple plaintiff firms (Rosen, Kaplan Fox, Pomerantz) announced investigations or encouraged investor inquiries alleging potential securities-law violations tied to disclosures — increasing litigation risk and investor uncertainty. Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire… Kaplan Fox Investigation Pomerantz Investigation
• Neutral Sentiment: Short-interest reports flagged changes in March, but published figures appear inconsistent; monitor for confirmed short sell activity and days‑to‑cover updates. (data sources flagged unusually low/zero figures).

Wall Street Analyst Weigh In

Several research firms recently commented on IBRX. BTIG Research began coverage on ImmunityBio in a report on Thursday, March 12th. They issued a "buy" rating and a $13.00 price objective for the company. Jefferies Financial Group upped their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, December 12th. HC Wainwright lifted their price target on shares of ImmunityBio from $10.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday, February 23rd. Piper Sandler reissued an "overweight" rating and set a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. Finally, D. Boral Capital restated a "buy" rating and set a $23.00 price objective on shares of ImmunityBio in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, ImmunityBio presently has a consensus rating of "Moderate Buy" and an average price target of $14.40.

ImmunityBio Stock Down 8.6%

The business has a fifty day simple moving average of $7.57 and a two-hundred day simple moving average of $4.17. The company has a market cap of $7.59 billion, a P/E ratio of -19.42 and a beta of -0.03.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. On average, equities analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Christobel Selecky sold 25,000 shares of the company's stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Barry J. Simon sold 75,000 shares of the stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total transaction of $900,750.00. Following the completion of the transaction, the director owned 2,850,821 shares in the company, valued at $34,238,360.21. The trade was a 2.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 501,967 shares of company stock valued at $4,466,412 over the last 90 days. 69.48% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ImmunityBio

A number of institutional investors have recently bought and sold shares of IBRX. Skandinaviska Enskilda Banken AB publ increased its position in ImmunityBio by 347.7% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 1,324,871 shares of the company's stock worth $3,246,000 after buying an additional 1,028,921 shares in the last quarter. Heights Capital Management Inc. bought a new position in shares of ImmunityBio in the third quarter worth about $16,152,000. Vanguard Group Inc. lifted its position in shares of ImmunityBio by 26.8% during the 3rd quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company's stock valued at $68,032,000 after buying an additional 5,837,898 shares in the last quarter. Armistice Capital LLC bought a new position in shares of ImmunityBio during the 2nd quarter valued at approximately $20,497,000. Finally, Rafferty Asset Management LLC grew its stake in shares of ImmunityBio by 79.2% during the 3rd quarter. Rafferty Asset Management LLC now owns 452,458 shares of the company's stock valued at $1,113,000 after acquiring an additional 199,990 shares during the period. 8.58% of the stock is owned by institutional investors.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.